A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of Baricitinib in Patients With Moderate-to-Severe Plaque Psoriasis
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007425/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib
in the treatment of participants with moderate to severe, chronic plaque psoriasis as
assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety
assessments.
提供机构：
Vivli
创建时间：
2021-09-29
